Skip to main content
Premium Trial:

Request an Annual Quote

Rolland Carlson, Tanja Dowe, Katleen Verleysen

Immunexpress has appointed Rolland Carlson, Tanja Dowe, and Katleen Verleysen to its board. The company also noted that Bea Arnold has stepped down from the board after a three-year tenure.

Carlson was appointed CEO of Immunexpress last month, and previously served as president and CEO at both WaferGen Biosystems and Asuragen. Dowe currently serves as CEO of Debiopharm Innovation Fund, the strategic corporate fund of Debiopharm Group. Verleysen is CEO of CellSeeQ. Prior to that, she held various positions at Pronota, including CEO and chief operating officer.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.